Navigation Links
PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Date:4/2/2008

nt, as set forth above, to accommodate the change in circumstances.

BroadOak Partners, LLC and Piper Jaffray Ltd. acted as financial advisors to PharmAthene and Avecia, respectively, in connection with the transaction.

rPA Anthrax Vaccine

Avecia's rPA vaccine, which has completed Phase II clinical testing, is a second generation rPA anthrax vaccine for use against human anthrax infection.

In February 2008, the Department of Health and Human Services (DHHS) issued a formal solicitation (Request for Proposals) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile (SNS). The solicitation outlines a requirement to procure 25 million doses of an rPA anthrax vaccine.

"There is currently an unmet need for a second generation anthrax vaccine that offers the potential for improved safety and convenience," said Mr. Wright. "We believe Avecia's vaccine is well positioned to meet this requirement, as it is a highly purified recombinant form of a single protein -- protective antigen (PA), which is produced using standard biotechnology processes. In preclinical and clinical studies the vaccine was shown to produce a vaccine-induced antibody response and was safe and well tolerated. If these results are confirmed in future studies, we believe this vaccine could prove to be a superior choice for procurement in the Strategic National Stockpile for civilian defense against anthrax threats."

About PharmAthene, Inc.

PharmAthene (Amex: PIP) was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead programs include Valortim(TM) for the prevention
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmAthene Reports Year-End 2007 Financial Results
2. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
3. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
4. PharmAthene to Delay Release of Full Year 2007 Financial Results
5. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
6. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. PharmAthene to Present at the BIO CEO & Investor Conference 2008
10. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  The Paul G. Allen Family Foundation announced ... to six groups of researchers with projects at the ... neuroscience: growing mature human brain cells in the laboratory. ... million over three years.  "This new ... especially significant because the field of neuronal maturation is ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/29/2015)... According to a new market ... (Portable & Non-Portable), Component (Accelerometer, Proximity Probe, & ... & Mining, & Others), & Geography - Global ... to reach $1,453.76 Million by 2020, at a ... tables and 92 figures spread through 205 pages ...
(Date:4/29/2015)... AlloSource ®, one of the ... and soft-tissue allografts for use in surgical procedures ... the launch of AlloSkin™ AC, an acellular dermal ... (CMS) also moved AlloSkin™ RT, a meshed human ... category for reimbursement. "AlloSource is committed ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4AlloSource Announces New Possibilities In Wound Care 2
... EMERYVILLE, Calif., Jan. 3, 2012  Bionovo, Inc. (NASDAQ: ... discovery and development of safe and effective treatments for ... entered into a $5 million securities purchase agreement with ... Socius Capital Group, LLC. (Logo: ...
... Jan. 3, 2012 Dear NeoStem Shareholders, ... back at 2011 - a transformative year for NeoStem (NYSE Amex: ... term catalysts that we expect to move the company forward in ... Progenitor Cell Therapy, LLC ("PCT") and Amorcyte, LLC ("Amorcyte"). , ...
... NEW YORK, Jan. 3, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0203539/Cytogenetics---technologiesmarkets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics ... cytogenetics in a broader sense rather than ...
Cached Biology Technology:Bionovo Announces $5 Million Financing 2Bionovo Announces $5 Million Financing 3Bionovo Announces $5 Million Financing 4NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Cytogenetics - Technologies, Markets and Companies 2Cytogenetics - Technologies, Markets and Companies 3Cytogenetics - Technologies, Markets and Companies 4Cytogenetics - Technologies, Markets and Companies 5Cytogenetics - Technologies, Markets and Companies 6Cytogenetics - Technologies, Markets and Companies 7Cytogenetics - Technologies, Markets and Companies 8Cytogenetics - Technologies, Markets and Companies 9Cytogenetics - Technologies, Markets and Companies 10Cytogenetics - Technologies, Markets and Companies 11
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... Lolle and colleagues from Purdue University published a paper in ... do not obey the laws of Mendelian inheritance (the idea ... found that these plants were demonstrating genetic traits from older ... of how genes are passed on. At the ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Mechanism ... 2013 FASEB Science Research Conference on Mechanism and ... 23 in Saxton Rivers, VT. The "Vermont Transcription ...
... mid-nineteenth century, maps have helped elucidate the deadly mysteries ... global mapping of infectious diseases is considerably unreliable and ... outbreaks, according to a new systematic mapping review of ... the 355 infectious diseases assessed in the review, 174 ...
Cached Biology News:Defying the laws of Mendelian inheritance 2Avoiding a cartography catastrophe 2
Request Info...
...
... to Atrophin 1 ( Abpromise for ... Synthetic peptide conjugated to KLH derived ... of Human Atrophin 1.(Note: the amino acid ... .) Entrez GeneID: ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: